Dr. Reddy's Laboratories peers

·Pharma & HealthChart ›

Companies like Dr. Reddy's Laboratorieslatest year

Dr. Reddy's LaboratoriesDRREDDY · FY26 · this company
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%
CiplaCIPLA · FY26
Open ›
Market cap₹1,10,313
P/E28.43×
Sales growth−2.4%
ROE11.8%
LupinLUPIN · FY26
Open ›
Market cap₹90,192
P/E16.90×
Sales growth+32.0%
ROE26.9%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
DRREDDY
FY26
SUNPHARMA
FY26
CIPLA
FY26
LUPIN
FY26
Peer
Average
Valuation — at last close
P/E26.49×36.77×28.43×◆ 16.90×27.37× -3%
P/B◆ 2.94×5.05×3.20×4.02×4.09× -28%
EV/EBITDA17.19×22.19×17.28×◆ 9.86×16.45× +5%
Market Cap₹1.12L Cr₹4.22L Cr₹1.10L Cr₹90,192 Cr₹2.07L Cr -46%
Growth
Revenue CAGR 3Y10.96%10.03%7.37%◆ 18.88%12.09% -9%
Revenue CAGR 5Y12.09%11.78%8.01%◆ 13.02%10.94% +11%
Net Income CAGR 3Y-2.66%10.57%10.88%◆ 128.70%50.05% -105%
Revenue YoY (latest Q)-1.48%10.46%-2.44%◆ 32.04%13.35% -111%
Net Income YoY (latest Q)-31.69%◆ 26.53%-37.08%16.01%1.82% -1841%
Profitability
EBITDA Margin19.15%30.33%20.89%◆ 31.53%27.58% -31%
Net Income Margin12.34%◆ 19.69%13.71%19.16%17.52% -30%
Return on Common Equity11.75%14.74%11.82%◆ 26.90%17.82% -34%
Return on Capital Employed11.30%18.48%13.87%◆ 32.38%21.58% -48%
Return on Assets7.73%11.46%9.67%◆ 15.85%12.33% -37%
Credit & Quality
Total Debt/Equity0.16×0.05×◆ 0.01×0.26×0.11× +50%
Interest Coverage11.76×43.65×◆ 85.90×17.12×48.89× -76%
Scale — latest FY
Revenue / Total Income₹33,700 Cr₹58,462 Cr₹28,163 Cr₹27,958 Cr₹38,194 Cr -12%
Net Income₹4,158 Cr₹11,509 Cr₹3,862 Cr₹5,355 Cr₹6,909 Cr -40%
Total Assets₹58,123 Cr₹1.09L Cr₹42,496 Cr₹38,365 Cr₹63,215 Cr -8%
EPS₹50.41₹47.8₹48.03₹116.75₹70.86 -29%
Book Value per Share₹453.79₹348.31₹426.24₹490.99₹421.85 +8%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.